PT  - JOURNAL ARTICLE
AU  - Mardani Abdul Halim
AU  - Izzah Madihah Rosli
AU  - Siti Shafika Muhamad Jaafar
AU  - Hoi-Min Ooi
AU  - Pui-Wei Leong
AU  - Shaharum Shamsuddin
AU  - Nazalan Najimudin
AU  - Ghows Azzam
TI  - <em>Withania somnifera</em> showed neuroprotective effect and increase longevity in <em>Drosophila</em> Alzheimer’s disease model
AID  - 10.1101/2020.04.27.063107
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.04.27.063107
4099  - http://biorxiv.org/content/early/2020/04/28/2020.04.27.063107.short
4100  - http://biorxiv.org/content/early/2020/04/28/2020.04.27.063107.full
AB  - Alzheimer’s disease is a complex neurodegenerative disease and is only unique to human. The disease is defined in human brain by the accumulation of amyloid beta in the parenchyma of the brain. Withania somnifera, commonly known as Ashwagandha is an Indian Ayurvedic medicine that has been used for centuries to treat countless range of human health problem. The active compound of Ashwagandha was shown to be beneficial in treating many neurodegenerative diseases including Alzheimer’s disease (AD). In this study, Drosophila melanogaster AD model was used to study the effect of Ashwagandha on the toxicity of beta amyloid and also the longevity effect of the compound. We found that 20 mg/mL of Ashwagandha was shown to be effective in rescuing the “rough eye phenotype” of AD Drosophila. Furthermore, Ashwagandha also promotes longevity in AD as well as wild-type Drosophila. The results above showed that Ashwagandha could potentially be a potent drug to treat AD as well as maintaining the wellbeing of cells.Competing Interest StatementThe authors have declared no competing interest.